NUZYRA® (omadacycline), available in the U.S. as a once-daily oral and intravenous antibiotic for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by select susceptible microorganisms.
Nuzyra (omadacycline) was added to the Joint Deployment Formulary (JDF), is currently being utilized by numerous MTF’s across all service branches, listed on the FDA Essential Medicine List and contracted with BARDA for bio-threat protection and antimicrobial resistance.